Antimicrobial peptides for treatment of infectious diseases
The present invention is directed to the peptides WKWLKKWIK, WRKFWKYLK, and RRWRVIVKW and use of said peptides as therapeutic agents for the prophylaxis and/or treatment of infections, in particular bacterial and/or fungal infections and diseases caused by bacterial and/or fungal infections.
1. A composition comprising a combination of the nonapeptides having the sequences WKWLKKWIK (SEQ ID NO.:1), WRKFWKYLK (SEQ ID NO.:2), and RRWRVIVKW (SEQ ID NO.:3).
2. The composition according to claim 1 for use in medicine.
3. The composition according to claim 1 , for use in the treatment of infections caused by bacteria and fungi.
4. The composition according to claim 1 , for use in the treatment of bacterial infections or diseases caused by bacteria.
5. The composition for use according to claim 4 , wherein the bacterial infection or disease is caused by infection with Gram-negative bacteria.
6. The composition for use according to claim 4 , wherein the bacterial infection or disease is caused by infection with Gram-positive bacteria.
7. The composition for use according to claim 4 , wherein the bacterial infection or disease is caused by infection with Mycobacterium tuberculosis.
8. The composition according to claim 1 , for use in the treatment of fungal infections or diseases caused by fungi.
9. The composition for use according to claim 8 , wherein the fungal infection or disease is caused by infection with pathogenic yeast species.
10. Pharmaceutical composition comprising a composition according to claim 1 and at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
11. Pharmaceutical composition according to claim 10 in the form of an artificial mother milk formulation or mother milk substitute suitable for oral delivery to newborns, toddlers and infants.
12. Pharmaceutical composition according to claim 10 in the form of a formulation for coating medical implants.
13. A composition comprising a nonapeptide having the sequence WKWLKKWIK (SEQ ID NO.:1).
14. A composition comprising a nonapeptide having the sequence WRKFWKYLK (SEQ ID NO.:2).
15. A composition comprising a nonapeptide having the sequence RRWRVIVKW (SEQ ID NO.:3).
16. The composition according to claim 13 for use in medicine.
17. The composition according to claim 13 , for use in the treatment of infections caused by bacteria and/or fungi.
18. The composition according to claim 13 , for use in the treatment of bacterial infections or diseases caused by bacteria.
19. The composition for use according to claim 18 , wherein the bacterial infection or disease is caused by infection with Gram-negative bacteria.
20. The composition for use according to claim 18 , wherein the bacterial infection or disease is caused by infection with Gram-positive bacteria.
21. The composition for use according to claim 18 , wherein the bacterial infection or disease is caused by infection with Mycobacterium tuberculosis.
22. The composition according to claim 13 , for use in the treatment of fungal infections or diseases caused by fungi.
23. The composition for use according to claim 22 , wherein the fungal infection or disease is caused by infection with pathogenic yeast species.
24. Pharmaceutical composition comprising a composition according to claim 13 and at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
25. Pharmaceutical composition according to claim 24 in the form of an artificial mother milk formulation or mother milk substitute suitable for oral delivery to newborns, toddlers and infants.
26. Pharmaceutical composition according to claim 24 in the form of a formulation for coating medical implants.
27. A method for the treatment of a disease, disorder or condition caused by, or accompanied by bacterial and/or fungal infection, comprising administering a pharmaceutically effective amount of a composition according to claim 1 to a subject in need thereof.
28. The method according to claim 27 , wherein the bacterial infection is caused by Gram-negative bacteria or Gram-positive bacteria.
29. The method according to claim 27 , wherein the fungal infection is caused by pathogenic yeast species.
30. The method according to claim 27 , wherein the subject in need thereof is a mammal or a bird.
31. The composition for use according to claim 9 , wherein the pathogenic yeast species is Candida albicans.
32. The composition for use according to claim 23 , wherein the pathogenic yeast species is Candida albicans.
33. The method according to claim 29 , wherein the pathogenic yeast species is Candida albicans.
34. The method according to claim 30 , wherein the mammal is a human, or the bird is a bird of prey.
35. The composition for use according to claim 6 , wherein the Gram-positive bacteria is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and Enterococcus faecalis.
36. The composition for use according to claim 20 , wherein the Gram-positive bacteria is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and Enterococcus faecalis.
37. The method according to claim 28 , wherein the Gram-negative bacteria is selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli , and Salmonella , or the Gram-positive bacteria is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis , and Mycobacterium tuberculosis.
38. The composition for use according to claim 5 , wherein the Gram-negative bacteria is selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli , and Salmonella.
39. The composition for use according to claim 19 , wherein the Gram-negative bacteria is selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli , and Salmonella .